Cargando…

Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease

BACKGROUND: Enkephalins of the opioid system exert several cardiorenal effects. Proenkephalin (PENK), a stable surrogate, is associated with heart failure (HF) development after myocardial infarction and worse cardiorenal function and prognosis in patients with HF. The association between plasma PEN...

Descripción completa

Detalles Bibliográficos
Autores principales: Emmens, Johanna E., ter Maaten, Jozine M., Brouwers, Frank P., Kieneker, Lyanne M., Damman, Kevin, Hartmann, Oliver, Schulte, Janin, Bakker, Stephan J. L., de Boer, Rudolf A., Voors, Adriaan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715404/
https://www.ncbi.nlm.nih.gov/pubmed/34716603
http://dx.doi.org/10.1002/clc.23729
_version_ 1784624120226381824
author Emmens, Johanna E.
ter Maaten, Jozine M.
Brouwers, Frank P.
Kieneker, Lyanne M.
Damman, Kevin
Hartmann, Oliver
Schulte, Janin
Bakker, Stephan J. L.
de Boer, Rudolf A.
Voors, Adriaan A.
author_facet Emmens, Johanna E.
ter Maaten, Jozine M.
Brouwers, Frank P.
Kieneker, Lyanne M.
Damman, Kevin
Hartmann, Oliver
Schulte, Janin
Bakker, Stephan J. L.
de Boer, Rudolf A.
Voors, Adriaan A.
author_sort Emmens, Johanna E.
collection PubMed
description BACKGROUND: Enkephalins of the opioid system exert several cardiorenal effects. Proenkephalin (PENK), a stable surrogate, is associated with heart failure (HF) development after myocardial infarction and worse cardiorenal function and prognosis in patients with HF. The association between plasma PENK concentrations and new‐onset HF in the general population remains to be established. HYPOTHESIS: We hypothesized that plasma PENK concentrations are associated with new‐onset HF in the general population. METHODS: We included 6677 participants from the prevention of renal and vascular end‐stage disease study and investigated determinants of PENK concentrations and their association with new‐onset HF (both reduced [HFrEF] and preserved ejection fraction [HFpEF]). RESULTS: Median PENK concentrations were 52.7 (45.1–61.9) pmol/L. Higher PENK concentrations were associated with poorer renal function and higher NT‐proBNP concentrations. The main determinants of higher PENK concentrations were lower estimated glomerular filtration rate (eGFR), lower urinary creatinine excretion, and lower body mass index (all p < .001). After a median 8.3 (7.8–8.8) years follow‐up, 221 participants developed HF; 127 HFrEF and 94 HFpEF. PENK concentrations were higher in subjects who developed HF compared with those who did not, 56.2 (45.2–67.6) versus 52.7 (45.1–61.6) pmol/L, respectively (p = .003). In competing‐risk analyses, higher PENK concentrations were associated with higher risk of new‐onset HF (hazard ratio [HR] = 2.09[1.47–2.97], p < .001), including both HFrEF (HR = 2.31[1.48–3.61], p < .001) and HFpEF (HR = 1.74[1.02–2.96], p = .042). These associations were, however, lost after adjustment for eGFR. CONCLUSIONS: In the general population, higher PENK concentrations were associated with lower eGFR and higher NT‐proBNP concentrations. Higher PENK concentrations were not independently associated with new‐onset HFrEF and HFpEF and mainly confounded by eGFR.
format Online
Article
Text
id pubmed-8715404
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-87154042022-01-06 Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease Emmens, Johanna E. ter Maaten, Jozine M. Brouwers, Frank P. Kieneker, Lyanne M. Damman, Kevin Hartmann, Oliver Schulte, Janin Bakker, Stephan J. L. de Boer, Rudolf A. Voors, Adriaan A. Clin Cardiol Clinical Investigations BACKGROUND: Enkephalins of the opioid system exert several cardiorenal effects. Proenkephalin (PENK), a stable surrogate, is associated with heart failure (HF) development after myocardial infarction and worse cardiorenal function and prognosis in patients with HF. The association between plasma PENK concentrations and new‐onset HF in the general population remains to be established. HYPOTHESIS: We hypothesized that plasma PENK concentrations are associated with new‐onset HF in the general population. METHODS: We included 6677 participants from the prevention of renal and vascular end‐stage disease study and investigated determinants of PENK concentrations and their association with new‐onset HF (both reduced [HFrEF] and preserved ejection fraction [HFpEF]). RESULTS: Median PENK concentrations were 52.7 (45.1–61.9) pmol/L. Higher PENK concentrations were associated with poorer renal function and higher NT‐proBNP concentrations. The main determinants of higher PENK concentrations were lower estimated glomerular filtration rate (eGFR), lower urinary creatinine excretion, and lower body mass index (all p < .001). After a median 8.3 (7.8–8.8) years follow‐up, 221 participants developed HF; 127 HFrEF and 94 HFpEF. PENK concentrations were higher in subjects who developed HF compared with those who did not, 56.2 (45.2–67.6) versus 52.7 (45.1–61.6) pmol/L, respectively (p = .003). In competing‐risk analyses, higher PENK concentrations were associated with higher risk of new‐onset HF (hazard ratio [HR] = 2.09[1.47–2.97], p < .001), including both HFrEF (HR = 2.31[1.48–3.61], p < .001) and HFpEF (HR = 1.74[1.02–2.96], p = .042). These associations were, however, lost after adjustment for eGFR. CONCLUSIONS: In the general population, higher PENK concentrations were associated with lower eGFR and higher NT‐proBNP concentrations. Higher PENK concentrations were not independently associated with new‐onset HFrEF and HFpEF and mainly confounded by eGFR. Wiley Periodicals, Inc. 2021-10-30 /pmc/articles/PMC8715404/ /pubmed/34716603 http://dx.doi.org/10.1002/clc.23729 Text en © 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigations
Emmens, Johanna E.
ter Maaten, Jozine M.
Brouwers, Frank P.
Kieneker, Lyanne M.
Damman, Kevin
Hartmann, Oliver
Schulte, Janin
Bakker, Stephan J. L.
de Boer, Rudolf A.
Voors, Adriaan A.
Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
title Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
title_full Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
title_fullStr Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
title_full_unstemmed Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
title_short Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
title_sort proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715404/
https://www.ncbi.nlm.nih.gov/pubmed/34716603
http://dx.doi.org/10.1002/clc.23729
work_keys_str_mv AT emmensjohannae proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT termaatenjozinem proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT brouwersfrankp proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT kienekerlyannem proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT dammankevin proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT hartmannoliver proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT schultejanin proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT bakkerstephanjl proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT deboerrudolfa proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease
AT voorsadriaana proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease